Safety and efficacy of anticoagulant administration in people with atrial fibrillation and advanced chronic kidney disease
Some emerging data suggest that DOACs, particularly rivaroxaban and apixaban, may offer improved safety profiles compared to VKAs in advanced CKD, with comparable efficacy. Observational studies indicate a potential advantage of DOACs in preventing stroke or systemic embolism (SSE) over VKAs. Large clinical trials including a no-anticoagulation arm and validation of risk stratification tools specific to advanced CKD are urgently needed.
Authors
- Witold Ignacy
- Krzysztof Irlik (ORCID: https://orcid.org/0000-0001-9699-1686)
- Katarzyna Nabrdalik (ORCID: https://orcid.org/0000-0002-0777-8048)
- Janusz Gumprecht (ORCID: https://orcid.org/0000-0001-7091-2118)
- Hanna Kwiendacz (ORCID: https://orcid.org/0000-0002-1256-0414)
- Gregory Y. H. Lip
- Aleksandra Grabska
Institutions
- Medical University of Białystok (PL)
- University of Liverpool (GB)
- Medical University of Silesia (PL)
- Liverpool Heart and Chest Hospital (GB)
- Liverpool John Moores University (GB)
- Aalborg University (DK)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1080/14740338.2025.2574492
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00